The GLP-1 analog exendin-4 enhanced prostate cancer sensitivity to enzalutamide by suppressing the PI3K/Akt/mTOR resistance pathway in both cell and animal models.
P < .05significance level for combination therapy reducing cancer cell invasion vs. enzalutamide alone
What the researchers found
Exendin-4 combined with enzalutamide significantly suppressed prostate cancer tumor growth compared to enzalutamide alone by inhibiting Akt and mTOR activation triggered by enzalutamide resistance.
Why it matters
Drug resistance is a major problem in prostate cancer treatment. Repurposing an existing diabetes peptide drug to overcome resistance could provide a faster path to clinical use than developing entirely new compounds.
The numbers in context
Exendin-4 plus enzalutamide produced significantly greater tumor shrinkage than either agent alone; Akt pathway suppressed.
How the study worked
In vitro experiments with LNCaP and CWR22RV1 prostate cancer cell lines plus in vivo xenograft mouse models. Measured tumor growth, invasion, migration, and key signaling pathway proteins.
Who was studied
Prostate cancer cell lines and mouse xenograft models
What this study cannot tell us
Animal study using xenograft models, which don't fully replicate human prostate cancer biology. Clinical doses and safety of exendin-4 in cancer patients haven't been established. One noted P-value (P < .5) appears to be a typo and may be less significant than intended.
How to read the evidence
Pre-clinical evidence from cell lines and mouse xenografts. Promising but requires human clinical trials to confirm therapeutic relevance.
When this study was published
Published in 2020. Interest in GLP-1 agonists for cancer applications has grown significantly since.
The bigger picture
GLP-1 receptor agonists are increasingly being studied for effects beyond diabetes, including potential anti-cancer properties. This study adds prostate cancer drug resistance to the list of conditions where these peptides may offer therapeutic benefit.
Questions still open
- Would this combination approach work in human clinical trials for castration-resistant prostate cancer?
- Do other GLP-1 analogs like semaglutide or liraglutide have similar anti-resistance effects?
- What is the optimal dosing of exendin-4 for anti-cancer effects versus its metabolic effects?
Common questions
What is enzalutamide resistance?
Is exendin-4 the same as drugs like Ozempic?
Read the original research
Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
The Prostate, 80(5), 367-375
Citation
Wenjing, He; Shao, Yuanyuan; Yu, Yi; Huang, Wei; Feng, Guoliang; Li, Junhe. (2020). Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.. The Prostate, 80(5), 367-375. https://doi.org/10.1002/pros.23951